Ra Capital Management, L.P. Buys 120,582 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 120,582 shares of Artiva Biotherapeutics stock in a transaction on Tuesday, July 21st. The shares were acquired at an average cost of $9.55 per share, for a total transaction of $1,151,558.10. Following the completion of the transaction, the director owned 17,098,479 shares of the company’s stock, valued at $163,290,474.45. This represents a 0.71% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. bought 41,319 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. bought 59,880 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $9.93 per share, for a total transaction of $835,351.32.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, with a total value of $3,351,032.83.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $10.00 on Thursday. The firm has a market cap of $247.10 million, a P/E ratio of -2.82 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53. The stock has a 50-day simple moving average of $8.92 and a 200-day simple moving average of $7.45.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ARTV shares. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. HC Wainwright boosted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.00.

Key Stories Impacting Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: RA Capital Management purchased an additional 41,319 ARTV shares at an average price of $9.99, investing approximately $413,000. This followed purchases of 59,880 shares on July 23, 84,124 shares on July 22, and 120,582 shares on July 21. The four transactions totaled roughly 306,000 shares and $3.0 million, increasing RA Capital’s ownership to more than 17.28 million shares. Continued insider accumulation can signal confidence in Artiva’s outlook and may provide a positive catalyst for the stock. Artiva Biotherapeutics director stock purchase report
• Positive Sentiment: Analyst coverage remains generally constructive. Artiva has an overall “Moderate Buy” rating and an average price target of $39, substantially above recent trading levels. Needham, Wedbush and Cantor Fitzgerald maintain bullish ratings, with Wedbush recently raising its target to $40. These targets reflect potential upside if Artiva’s off-the-shelf natural-killer-cell therapy pipeline advances successfully. Artiva Biotherapeutics analyst ratings
• Neutral Sentiment: Other institutional investors, including Bank of America, Jane Street, Qube Research & Technologies and Bridgeway Capital Management, have initiated or increased positions. However, the reported positions are relatively small and do not represent a major change in institutional ownership.
• Negative Sentiment: Artiva’s financial profile remains a risk. The company’s latest quarterly loss of $0.95 per share was worse than the $0.88 analyst consensus, and analysts expect a full-year loss of approximately $2.45 per share. Wall Street Zen and Weiss Ratings have issued sell-oriented views, underscoring concerns about ongoing cash needs, clinical execution and the absence of commercial revenue.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC grew its position in shares of Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares in the last quarter. Marshall Wace LLP bought a new position in Artiva Biotherapeutics during the 4th quarter valued at $341,000. Jane Street Group LLC bought a new position in Artiva Biotherapeutics during the 2nd quarter valued at $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.